UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 7, 2006
Lifeline Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Colorado
|
|
000-30489
|
|
90-0224471 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
| |
|
|
| 6400 South Fiddler’s Green Circle, Suite 1970, Greenwood Village,
|
|
CO 80111 |
| |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (720) 488-1711
6400 South Fiddler’s Green Circle, Suite 1750, Englewood, CO 80111
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
ITEM 7.01 Regulation FD Disclosure
Beginning September 7, 2006 and thereafter, management of the company intends to hold
discussions and/or meetings with shareholders. The attached presentation, dated September 2006,
includes the information to be discussed. The presentation is attached as Exhibit 99.1 hereto.
ITEM 9.01. Exhibits
99.1 Presentation dated “September 2006”
2